ATE206930T1 - Verwendung von osteoblast-proliferationsfaktor - Google Patents

Verwendung von osteoblast-proliferationsfaktor

Info

Publication number
ATE206930T1
ATE206930T1 AT95111224T AT95111224T ATE206930T1 AT E206930 T1 ATE206930 T1 AT E206930T1 AT 95111224 T AT95111224 T AT 95111224T AT 95111224 T AT95111224 T AT 95111224T AT E206930 T1 ATE206930 T1 AT E206930T1
Authority
AT
Austria
Prior art keywords
proliferation factor
osteoblast proliferation
bone
diseaese
prevention
Prior art date
Application number
AT95111224T
Other languages
English (en)
Inventor
Akira Kudo
Tohru Nakanishi
Masaharu Takigawa
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Application granted granted Critical
Publication of ATE206930T1 publication Critical patent/ATE206930T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AT95111224T 1994-07-22 1995-07-18 Verwendung von osteoblast-proliferationsfaktor ATE206930T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20125794A JP3738281B2 (ja) 1994-07-22 1994-07-22 新規な骨芽細胞増殖因子

Publications (1)

Publication Number Publication Date
ATE206930T1 true ATE206930T1 (de) 2001-11-15

Family

ID=16437950

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95111224T ATE206930T1 (de) 1994-07-22 1995-07-18 Verwendung von osteoblast-proliferationsfaktor

Country Status (14)

Country Link
US (1) US6080720A (de)
EP (1) EP0704219B1 (de)
JP (1) JP3738281B2 (de)
KR (1) KR100361717B1 (de)
AT (1) ATE206930T1 (de)
AU (1) AU693567B2 (de)
CA (1) CA2154403A1 (de)
DE (1) DE69523250T2 (de)
DK (1) DK0704219T3 (de)
ES (1) ES2161809T3 (de)
FI (1) FI953514L (de)
HU (1) HU217082B (de)
NO (1) NO952912L (de)
PT (1) PT704219E (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2787208C (en) * 2010-01-15 2017-06-06 University Of Medicine And Dentistry Of New Jersey Use of vanadium compounds to accelerate bone healing
US20140322292A1 (en) 2010-12-10 2014-10-30 Rutgers, The State University Of New Jersey Insulin-mimetics as therapeutic adjuncts for bone regeneration
WO2013006798A1 (en) 2011-07-06 2013-01-10 University Of Medicine And Dentistry Of New Jersey Vandium compounds as therapeutic adjuncts for cartilage regeneration and repair
CA2820297C (en) 2010-12-10 2019-06-25 University Of Medicine And Dentistry Of New Jersey Implantable devices coated with insulin-mimetic agent composites and methods thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95511A (en) * 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
AU2460595A (en) * 1994-05-06 1995-11-29 Regeneron Pharmaceuticals, Inc. Methods based on the role of neurotrophin 3 in female reproduction

Also Published As

Publication number Publication date
JPH0834744A (ja) 1996-02-06
KR100361717B1 (ko) 2003-07-07
FI953514A7 (fi) 1996-01-23
NO952912D0 (no) 1995-07-21
EP0704219A3 (de) 1997-12-10
JP3738281B2 (ja) 2006-01-25
HU9502202D0 (en) 1995-09-28
ES2161809T3 (es) 2001-12-16
DE69523250D1 (de) 2001-11-22
EP0704219B1 (de) 2001-10-17
EP0704219A2 (de) 1996-04-03
FI953514L (fi) 1996-01-23
CA2154403A1 (en) 1996-01-23
AU693567B2 (en) 1998-07-02
HU217082B (hu) 1999-11-29
NO952912L (no) 1996-01-23
AU2710595A (en) 1996-02-01
DE69523250T2 (de) 2002-07-04
KR960003741A (ko) 1996-02-23
US6080720A (en) 2000-06-27
HUT73185A (en) 1996-06-28
FI953514A0 (fi) 1995-07-20
PT704219E (pt) 2002-03-28
DK0704219T3 (da) 2002-02-04

Similar Documents

Publication Publication Date Title
UA29505C2 (uk) Фармацевтична композиція для лікування і/або профілактики розрідження кістки і спосіб лікування і/або профілактики розрідження кістки у ссавців
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
DE69332732D1 (de) Pharmazeutische Zusammensetzung und Methode zur Behandlung von Hyperlipidämie und Arterioskerose
DE69825292D1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
ATE256463T1 (de) Pharmazeutische zubereitung zur verwendung in der behandlung von diabetes
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
HUT77380A (hu) Kombinált gyógyszerkészítmény alkalmazása sclerosis multiplex (MS) és más demielizáló állapotok kezelésére
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
DE69431046D1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
DE69420776D1 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
GR3023596T3 (en) Neural implant system
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
ATE206930T1 (de) Verwendung von osteoblast-proliferationsfaktor
DE69314586D1 (de) Arzneimittelzusammensetzung enthaltend TCF-II
DE69424747D1 (de) Pharmazeutische Zusammensetzung zur Vorbeugung oder Behandlung von Knochenbrüchen
NO984196D0 (no) Fremgangsmåte for behandling av stoffmisbruk
NO20010984D0 (no) Anvendelse av R(+)-<alfa>-(2,3-dimetoksyfenyl)-1-[2-(4- fluorfenyl)etyl]-4-piperidinmetanol for behandling av søvnforstyrrelser
IL103499A0 (en) Pharmaceutical compositions for treating anxiety in benzodiazepine withdrawn patients
SU1833719A1 (ru) Cпocoб xиpуpгичeckoгo лeчehия cпиhhomoзгoboй гpыжи, coчetaющeйcя c гидpoцeфaлиeй
UA10221A (uk) Спосіб лікування рецидивного бронхіту у дітей
SG64899A1 (en) Method and composition for treatment of patients having decompsated liver disease

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee